BBC NEWS | UK | Scotland | Tayside and Central | Study uncovers new diabetes genes: "Scientists have been able to identify three new genes which they say will bring them closer to understanding the causes of diabetes.
The discovery follows patient data gathered in Tayside and Fife by researchers from Dundee University.
Scientists from Oxford and Exeter have been working on the study.
The three new genes that predispose people to develop Type 2 diabetes brings the total number of genes involved to nine."
4.28.2007
S.F. becomes biological choice / City's starting to attract more biotechnology firms
S.F. becomes biological choice / City's starting to attract more biotechnology firms: "San Francisco officials have long lamented the dearth of biotech companies in the city, despite the fact that scores of companies located elsewhere have arisen from UCSF's research. City officials have campaigned to lure some of the companies away from the suburban biotech centers surrounding San Francisco, promoting the Mission Bay development near China Basin as the big hope to build a significant cluster.
But it turns out that, with almost no public attention, biotech companies have been sprouting inside the city limits -- near BART stations, in the Financial District, around the Caltrain station and AT&T Park. And it has happened before most of Mission Bay's lab and office space has opened."
But it turns out that, with almost no public attention, biotech companies have been sprouting inside the city limits -- near BART stations, in the Financial District, around the Caltrain station and AT&T Park. And it has happened before most of Mission Bay's lab and office space has opened."
Firms join on biotech
Firms join on biotech: "BASF and Monsanto Company recently announced a long-term joint research and development and commercialization collaboration in plant biotechnology that will focus on the development of high yielding crops and crops that are more tolerant to adverse environmental conditions such as drought.
The collaboration went into effect immediately upon the announcement being made March 21, according to a joint statement issued by Monsanto and BASF.
Over the life of the project, the two companies will dedicate a joint budget of up to $1.5 billion to fund a dedicated pipeline of yield and stress tolerance traits for corn, soybeans, cotton and canola. "
The collaboration went into effect immediately upon the announcement being made March 21, according to a joint statement issued by Monsanto and BASF.
Over the life of the project, the two companies will dedicate a joint budget of up to $1.5 billion to fund a dedicated pipeline of yield and stress tolerance traits for corn, soybeans, cotton and canola. "
SSRN-Authorized Generics: A Prescription for Hatch-Waxman Reform by Tom Chen
SSRN-Authorized Generics: A Prescription for Hatch-Waxman Reform by Tom Chen: "Abstract:
Authorized generics present the latest controversy in the perennial battle between pioneer and generic drug manufacturers. Under these arrangements, a pioneer firm will “authorize” a generic version of its brand-name drug to enter the market during another generic competitor's 180-day exclusivity period. This practice has generated intense debate within the pharmaceutical industry regarding its potential impact on Paragraph IV patent challenges, in addition to the proper operation and intent of the Hatch-Waxman Act. Because of the immense economic and public health consequences at stake, and previous patterns of Hatch-Waxman abuse, the Federal Trade Commission has recently launched an investigation of authorized generics. "
Authorized generics present the latest controversy in the perennial battle between pioneer and generic drug manufacturers. Under these arrangements, a pioneer firm will “authorize” a generic version of its brand-name drug to enter the market during another generic competitor's 180-day exclusivity period. This practice has generated intense debate within the pharmaceutical industry regarding its potential impact on Paragraph IV patent challenges, in addition to the proper operation and intent of the Hatch-Waxman Act. Because of the immense economic and public health consequences at stake, and previous patterns of Hatch-Waxman abuse, the Federal Trade Commission has recently launched an investigation of authorized generics. "
Biotech contenders - baltimoresun.com
Biotech contenders - baltimoresun.com: "The state has a breadth in its biotechnology companies and several possibilities to become the leader"
Variant Strain of Chlamydia May Go Undetected
Variant Strain of Chlamydia May Go Undetected: "Amid reports of a variant strain of Chlamydia trachomatis (vCT) that is not detected by certain molecular tests, BD Diagnostics, a segment of BD (NYSE: BDX), announced today that testing performed using the BD ProbeTec(TM) Chlamydia trachomatis (CT) amplified DNA assay confirms the product's ability to detect this organism analytically."
Ranbaxy Receives Final Approval to Manufacture and Market Zolpidem Tablets for Insomnia
Ranbaxy Receives Final Approval to Manufacture and Market Zolpidem Tablets for Insomnia: "Ranbaxy Laboratories Limited (RLL), announced today that the Company has received final approval from the U.S. Food and Drug Administration to manufacture and market Zolpidem Tartrate Tablets, 5mg and 10mg."
Report Finds Massachusetts's Life Sciences Sector Leads the Nation, Yet New Competition, Systemic Challenges Threaten Future Growth
Report Finds Massachusetts's Life Sciences Sector Leads the Nation, Yet New Competition, Systemic Challenges Threaten Future Growth: "Despite the success of Massachusetts' life sciences industry, the PwC survey found signs that future growth may be hampered by the state's high cost of living, shortage of affordable housing, transportation issues resulting in long commutes, a diminishing pipeline of math and science students and the high cost of doing business in the state."
Press Release: Report Finds Massachusetts's Life Sciences Sector Leads the Nation - FierceBiotech
Press Release: Report Finds Massachusetts's Life Sciences Sector Leads the Nation - FierceBiotech: "BOSTON, April 26 -- Massachusetts' life sciences sector is the second-biggest driver of growth in the state's economy and represents the world's largest concentration of life sciences firms per square mile, according to a report released today by PricewaterhouseCoopers, the Massachusetts Technology Collaborative and the New England Healthcare Institute. Yet the report's authors warn that increased competition from other states means Massachusetts must do more to protect its leadership position."
Press Release: Spherix Signs Letter of Intent for the Sale of Its Information Subsidiary - FierceBiotech
Press Release: Spherix Signs Letter of Intent for the Sale of Its Information Subsidiary - FierceBiotech: "BELTSVILLE, Md., April 26 -- Spherix Incorporated has signed a letter of intent to sell the stock of its subsidiary, InfoSpherix Incorporated, to The Active Network Inc. Terms of the deal have not been disclosed. InfoSpherix contracts with government agencies to design, host, and operate park reservation services and public service contact centers."
Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Canc
Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers: "ROCKVILLE, Md., April 27 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today reported that clinical and preclinical evidence continues to emerge demonstrating that its TRAIL receptor antibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), have significant potential for use in the treatment of a broad range of cancers."
Researchers Discover First Gene Associated With Idiopathic Scoliosis
Researchers Discover First Gene Associated With Idiopathic Scoliosis: "DALLAS, April 26 /PRNewswire/ -- Researchers at Texas Scottish Rite Hospital for Children (TSRHC), one of the nation's leading pediatric centers for research and the treatment of orthopaedic conditions, have identified the first gene -- CHD7 -- associated with idiopathic scoliosis (I.S.), the most common spinal deformity in children."
LuBlog: Biotech to drive next wave of electronics - ISS U.S. Recap
LuBlog: Biotech to drive next wave of electronics - ISS U.S. Recap: "What does biotech have to do with semiconductors?
Steve Jurvetson, managing director of Draper Fisher Jurvetson, a lead venture capitalist in Silicon Valley (known for nano and cleantech and overall technology) believes that bio will inspire the next generation of electronics. He spoke of the work happening at Harvard and other places that essentially creates an interface between the body and electronics. Researchers at Harvard have been able to functionalize virus’ and DNA to send and receive signals – quite amazing stuff. It is the work of VC’s to think far out in the future, but not too practical for equipment and materials companies that are looking for near term sources of revenues."
Steve Jurvetson, managing director of Draper Fisher Jurvetson, a lead venture capitalist in Silicon Valley (known for nano and cleantech and overall technology) believes that bio will inspire the next generation of electronics. He spoke of the work happening at Harvard and other places that essentially creates an interface between the body and electronics. Researchers at Harvard have been able to functionalize virus’ and DNA to send and receive signals – quite amazing stuff. It is the work of VC’s to think far out in the future, but not too practical for equipment and materials companies that are looking for near term sources of revenues."
People's Daily Online -- Zambia continues to be cautious in dealing with genetically modified organisms
People's Daily Online -- Zambia continues to be cautious in dealing with genetically modified organisms: "Zambian President Levy Mwanawasa reiterated Friday that his government will continue to act with caution when it comes to dealing with issues of genetically modified organisms (GMOs)."
PharmaLive: Cytos Biotechnology Enters Exclusive License Agreement With Novartis to Develop, Manufacture and Commercialize Novel Vaccine for Treatment
PharmaLive: Cytos Biotechnology Enters Exclusive License Agreement With Novartis to Develop, Manufacture and Commercialize Novel Vaccine for Treatment of Nicotine Addiction: "ZURICH , Switzerland, April 25, 2007 /PRNewswire-FirstCall/ -- Cytos Biotechnology AG announced today that it has entered into an exclusive global commercial license agreement with Novartis to develop, manufacture and commercialize CYT002-NicQb, a therapeutic vaccine in phase II clinical development for the treatment of nicotine addiction."
Chinese AIDs Drug Set for Clinical Tests
Chinese AIDs Drug Set for Clinical Tests: "Scientists are about to begin clinical testing of a new anti-AIDs drug developed in Shanghai, China. The orally-administered drug works by inhibiting a cellular surface protein known as CCR5 which facilitates the HIV virus’ entry into cells. According to an article in People’s Daily Online, the Chinese pharmaceutical industry generally lags behind other countries and the companies are inexperienced in global marketing of new drugs. However, a contract has already been signed with an Australian firm for international marketing of the new drug, called Nifeviroc. An American drug with a similar mechanism is already in third stage clinical trials. However, based on laboratory tests, it is anticipated that Nifeviroc will perform equally well, and it is expected to cost less than its foreign counterpart."
CTV.ca | Canadian researchers 'create' leukemia stem cell
CTV.ca | Canadian researchers 'create' leukemia stem cell: "TORONTO -- Imagine if scientists could peer into the blood and see the very first aberrant cells that will give birth to leukemia and then watch as the disease slowly progresses and takes over the body.
Well, Canadian researchers have done just that - converted normal human blood cells into leukemia stem cells, then transplanted them into lab mice and witnessed the disease unfold.
'You can study certain things about human cancer by studying the cancer itself,' said principal researcher John Dick, a stem cell biologist at Princess Margaret Hospital in Toronto. 'But the one thing you can't study is what were the sequence of events that happened in the months and years before that process that actually led to that disease.'
The groundbreaking research involved infecting cells from umbilical cord blood with a virus engineered to carry one of the genes known to cause certain types of leukemia. The genetic alteration created primitive leukemia stem cells, which were then injected into specially bred lab mice."
Well, Canadian researchers have done just that - converted normal human blood cells into leukemia stem cells, then transplanted them into lab mice and witnessed the disease unfold.
'You can study certain things about human cancer by studying the cancer itself,' said principal researcher John Dick, a stem cell biologist at Princess Margaret Hospital in Toronto. 'But the one thing you can't study is what were the sequence of events that happened in the months and years before that process that actually led to that disease.'
The groundbreaking research involved infecting cells from umbilical cord blood with a virus engineered to carry one of the genes known to cause certain types of leukemia. The genetic alteration created primitive leukemia stem cells, which were then injected into specially bred lab mice."
California Stem Cell Report: More Fallout from CIRM's Facilities Meeting
California Stem Cell Report: More Fallout from CIRM's Facilities Meeting: "The Friday the 13 meeting of the CIRM Facilities group generated additional coverage in the last few days. That was the meeting that precipitated the early departure of the president of the California stem cell agency. The chair of the Facilities group also resigned without explanation following the session. "
4.27.2007
Press Release: Cerus Corporation Considering Spinning off Immunotherapy Business - FierceBiotech
Press Release: Cerus Corporation Considering Spinning off Immunotherapy Business - FierceBiotech: "CONCORD, Calif. - Cerus Corporation announced today it will explore strategic alternatives for its immunotherapy programs. The Company will consider several possible business structures, including partnering some or all of the programs within its immunotherapy business with companies having established programs in immunology or in cancer and infectious disease indications, combining its immunotherapy business with another public or private company, or spinning out the business for an equity interest in a newly-formed immunotherapy company."
Second look reveals potential for Columbia Labs drug - FierceBiotech
Second look reveals potential for Columbia Labs drug - FierceBiotech: "After reporting last February that progesterone gel failed to hit its primary endpoint and all secondary endpoints for preventing preterm births, Columbia Laboratories says that a second look at the late-stage data showed evidence that the drug could delay cervical shortening, which increases preterm delivery risks."
Health Blog : Report: AstraZeneca Could Dump MedImmune Vaccine
Health Blog : Report: AstraZeneca Could Dump MedImmune Vaccine: "AstraZeneca may unload MedImmune’s vaccine franchise after closing the $15 billion acquisition, according to an unnamed “senior source” quoted on the Web site of the British magazine The Business."
VentureBeat � Cellerant Therapeutics raises $4.4M for stem-cell therapeutics
VentureBeat � Cellerant Therapeutics raises $4.4M for stem-cell therapeutics: "Cellerant Therapeutics, a San Carlos, Calif. developer of stem cell therapeutics for things like sickle cell disease treatment, has raised $4.4 million in a second round financing."
A Bearish Case for Amgen
A Bearish Case for Amgen: "The recent upturn has reawakened hopes that Amgen will start a run back to its glory days. But the weekly chart points out several reasons to be highly skeptical about this issue's prospects in the next one to two quarters. Let's start with the shape of the decline off the 2005 high."
Health Blog : Biogen Idec CEO Prescribes Policy Fixes
Health Blog : Biogen Idec CEO Prescribes Policy Fixes: "Biogen Idec chief James Mullen lands on the WSJ op-ed page this morning with some industry-friendly tips for a Congress that has been making noises industry doesn’t like. Mullen, also chairman of the trade group Biotechnology Industry Organization, makes three main points on behalf of biotech companies."
Health Blog : Mixed Picture for Boston Scientific
Health Blog : Mixed Picture for Boston Scientific: "It’s been a tough year for Boston Scientific, with shares down by some 40%. But some analysts remain optimistic about a turnaround. In a piece posted today on WSJ.com, Worth Civils lays out the bullish and bearish takes on the medical device manufacturer."
VentureBeat � Biotech financing: Not everyone gets a turn at the firehose
VentureBeat � Biotech financing: Not everyone gets a turn at the firehose: "Every trend has its counterexamples, and the rush of venture funding into biotechnology is no exception.
VentureWire reports today (subscription required) on the case of Sequella, a small Rockville, Md., biotech working on new therapies for drug-resistant tuberculosis (whose bacterium is pictured at left). The company is seeking $20 million to put SQ109 (link to PDF), its leading TB-drug candidate, through mid-stage human testing. So far, however, the company isn’t finding many takers:"
VentureWire reports today (subscription required) on the case of Sequella, a small Rockville, Md., biotech working on new therapies for drug-resistant tuberculosis (whose bacterium is pictured at left). The company is seeking $20 million to put SQ109 (link to PDF), its leading TB-drug candidate, through mid-stage human testing. So far, however, the company isn’t finding many takers:"
GENE THERAPY | Daily Policy Digest | NCPA
GENE THERAPY | Daily Policy Digest | NCPA: "GENE THERAPY
Over the past 30 years, biotechnology has come to represent an American success story, says James C. Mullen, president and CEO of Biogen Idec, Inc. and chairman of the Biotechnology Industry Organization.
* With 1,400 public and private companies employing tens of thousands of people, the United States is universally considered to be the global biotech leader.
* America can brag that its biotechnology companies capture about 75 percent of the global revenue, have a highly educated, well-paid work force, conduct most of their research, development and manufacturing here at home, and are a net exporter in foreign trade.
* In fact, in the pursuit of scientific excellence, several of the larger European pharmaceutical companies have chosen to 'outsource' biotech-related R&D operations to the United States.
But perhaps the most important metric for America's biotechnology industry is the impact on the lives of real patients. Simply put, the industry has helped transform science into real cures -- which has meant less death and disability for patients, says Mullen.
Yet while we have seen great progress, the unmet need is considerable:"
Over the past 30 years, biotechnology has come to represent an American success story, says James C. Mullen, president and CEO of Biogen Idec, Inc. and chairman of the Biotechnology Industry Organization.
* With 1,400 public and private companies employing tens of thousands of people, the United States is universally considered to be the global biotech leader.
* America can brag that its biotechnology companies capture about 75 percent of the global revenue, have a highly educated, well-paid work force, conduct most of their research, development and manufacturing here at home, and are a net exporter in foreign trade.
* In fact, in the pursuit of scientific excellence, several of the larger European pharmaceutical companies have chosen to 'outsource' biotech-related R&D operations to the United States.
But perhaps the most important metric for America's biotechnology industry is the impact on the lives of real patients. Simply put, the industry has helped transform science into real cures -- which has meant less death and disability for patients, says Mullen.
Yet while we have seen great progress, the unmet need is considerable:"
Youth Curry - Insight on Indian Youth: 'Biotech boom' - but where are the jobs?
Youth Curry - Insight on Indian Youth: 'Biotech boom' - but where are the jobs?: "Everyone wants to enter a field which is 'hot'. One such field is biotech. You would have read innumerable articles on the scope of bitechnology. The jobs opening up in the sector. And of course the poster pin up company Biocon.
As a report in the Hindu notes: Career counsellors and those engaged in educational guidance... are flooded with inquiries about biotechnology courses and their scope. Biotechnology today looks like what information technology was in the 1990s. "
As a report in the Hindu notes: Career counsellors and those engaged in educational guidance... are flooded with inquiries about biotechnology courses and their scope. Biotechnology today looks like what information technology was in the 1990s. "
Novartis says Japanese study shows Diovan reduces cardiovascular, stroke risk - Forbes.com
Novartis says Japanese study shows Diovan reduces cardiovascular, stroke risk - Forbes.com: "ZURICH (Thomson Financial) - Novartis AG said results from an independent study in Japan show use of its blood pressure drug Diovan, in combination with conventional therapy, can significantly reduce the risk of cardiovascular events and strokes."
PS3 doubles Folding@home capacity - FierceGameBiz
PS3 doubles Folding@home capacity - FierceGameBiz: "The impact of Sony PlayStation 3 owners participating in Stanford University's Folding@home project has been noticeable--the program's capacity has doubled due to PS3 owners contributing their consoles' Cell processors to the program. Folding@home aims to utilize civilian processing power to assist in the analysis of protein folding, which could aid in curing diseases. 'Thanks to PS3, we have performed simulations in the first few weeks that would normally take us more than a year to calculate,' said associate professor of chemistry and Folding@home program lead Vijay Pande. 'We are now gearing up for new simulations that will continue our current studies of Alzheimer's and other diseases.'"
Novartis' influenza vaccine Optaflu recommended for EU approval - Forbes.com
Novartis' influenza vaccine Optaflu recommended for EU approval - Forbes.com: "ZURICH (Thomson Financial) - Novartis AG said that the Committee for Medicinal Products for Human Use (CHMP) has recommended European approval for its influenza vaccine Optaflu."
FDA sends Merck a Dear John letter on Arcoxia - Apr. 27, 2007
FDA sends Merck a Dear John letter on Arcoxia - Apr. 27, 2007: "NEW YORK (CNNMoney.com) -- The FDA shot down Merck's application for an arthritis painkiller that has been widely criticized for its resemblance to Vioxx.
The Food and Drug Administration issued Merck (down $0.78 to $51.65, Charts, Fortune 500) a 'non-approvable letter' for Arcoxia, the drugmaker said on Friday. The letter said Merck needs to provide more test results showing that Arcoxia's benefits outweigh its risks before it has another chance of getting approved."
The Food and Drug Administration issued Merck (down $0.78 to $51.65, Charts, Fortune 500) a 'non-approvable letter' for Arcoxia, the drugmaker said on Friday. The letter said Merck needs to provide more test results showing that Arcoxia's benefits outweigh its risks before it has another chance of getting approved."
Hollis-Eden to Cut One-Fourth of Staff | Chron.com - Houston Chronicle
Hollis-Eden to Cut One-Fourth of Staff | Chron.com - Houston Chronicle: "SAN DIEGO — Drug developer Hollis-Eden Pharmaceuticals Inc. said Friday its chief financial officer is leaving and the company will cut 25 percent of its work force, 18 jobs, in a move to reduce cash usage for the rest of year."
MPM strikes deal to invest in Indian biotechs - FierceBiotech
MPM strikes deal to invest in Indian biotechs - FierceBiotech: "The U.S. venture firm MPM Capital has created a partnership with India's Reliance Life Sciences aimed at injecting fresh capital into the subcontinent's life sciences industry. In the deal, RLS has become a partner in MPM BioVentures IV, a newly-closed $550 million fund which will budget a portion of its investment dollars for Indian biotech companies. The two firms are also considering the potential of a new seed fund that would be devoted to Indian companies. The move is a welcome development for India's biotech sector, which has been long on potential and short on cash. It also offers another glimpse at the increasingly global structure of drug development, as companies develop international strategies for cutting costs and shortening development time frames."
Generics Challenge FDA's Decision On Pfizer Drug - Seeking Alpha
Generics Challenge FDA's Decision On Pfizer Drug - Seeking Alpha: "Aaron F. Barkoff submits: Apparently not too many companies other than Pfizer (PFE) are happy with the FDA's decision last week regarding Norvasc (amlodipine besylate) exclusivity.
On Monday, Mylan (MYL), Apotex, and Teva (TEVA) all filed motions with the U.S. District Court for the District of Columbia for injunctive relief from FDA's decision. Yesterday, everyone filed briefs in opposition to each others' motions."
On Monday, Mylan (MYL), Apotex, and Teva (TEVA) all filed motions with the U.S. District Court for the District of Columbia for injunctive relief from FDA's decision. Yesterday, everyone filed briefs in opposition to each others' motions."
Digital50: News and more Business News
Digital50: News and more Business News: "WASHINGTON-(Business Wire)-April 27, 2007 - Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), issued today the following statement praising the inclusion of Small Business Innovation Research (SBIR) grant eligibility reform in Speaker Nancy Pelosi's House Innovation Agenda:"
Survey Suggests RFID Could Aid Clinical Trials
Survey Suggests RFID Could Aid Clinical Trials: "Developing new drugs takes a lot of time and a lot of money. RFID can help save both, especially during the clinical trials phase, according to a study released this week by ChainLink Research. "
FDA Approves Once-Daily Veramyst(TM) (fluticasone furoate) Nasal Spray for Treatment of Seasonal and Year-Round Allergy Symptoms in Adults and Childre
FDA Approves Once-Daily Veramyst(TM) (fluticasone furoate) Nasal Spray for Treatment of Seasonal and Year-Round Allergy Symptoms in Adults and Children as Young as Two Years: "RESEARCH TRIANGLE PARK, N.C., April 27 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration today approved once-daily Veramyst(TM) (fluticasone furoate) Nasal Spray to treat seasonal and year- round allergy symptoms in adults and children two years of age and older. Veramyst will be available by prescription nationwide by late May 2007."
CQ HealthBeat News - Hatch May Soon Introduce Compromise Bill on Biotech Generics
CQ HealthBeat News - Hatch May Soon Introduce Compromise Bill on Biotech Generics: "Sen. Orrin G. Hatch, R-Utah, said Wednesday that he is likely to introduce a bill soon aimed at striking a compromise on the issue of bringing generic versions of biotech drugs to market. But the move may not come in time for Senate floor action next week on a prescription drug bill (S 1082), widely viewed as must-pass legislation this year.
Speaking at a forum sponsored by the U.S. Chamber of Commerce, Hatch said he doesn’t expect generic biotech marketing provisions — whether written by him or other senators — to be part of S 1082. But he didn’t rule out the possibility, noting that congressional aides “literally have been working day and night” on the issue."
Speaking at a forum sponsored by the U.S. Chamber of Commerce, Hatch said he doesn’t expect generic biotech marketing provisions — whether written by him or other senators — to be part of S 1082. But he didn’t rule out the possibility, noting that congressional aides “literally have been working day and night” on the issue."
Health Blog : FDA Approves Magnum PI
Health Blog : FDA Approves Magnum PI: "When we read yesterday that the FDA approved ArthroCare’s Magnum PI knotless implant system for attaching soft tissue to bone, we had to learn more. What does a plastic device (pictured at right) used by orthopedic surgeons to repair torn rotator cuffs have to do with the mustachioed private eye (pictured at left) with the sweet ride and the swanky digs?"
AstraZeneca's MedImmune Acquisition Should Receive Regulatory Approval - Seeking Alpha
AstraZeneca's MedImmune Acquisition Should Receive Regulatory Approval - Seeking Alpha: "The M & A Researcher submits: The AstraZeneca (AZN) -MedImmune Inc. (MEDI) acquisition deal is the largest biotech deal to surface since the Immunex/Amgen (AMGN) transaction almost five years ago. There is one simple factor that applies to biotech deals with respect to competition-related reviews (particularly the DOJ/FTC): a specific niche overlap(s) must exist where one or both of the companies are dominant in that niche in order to draw any sort of antitrust interest."
Science Journal (Almost) Polices the Blogosphere: Sciam Observations
Science Journal (Almost) Polices the Blogosphere: Sciam Observations: "Anyway, on Tuesday, over at the ScienceBlog Retrospectacle, neuroscience PhD student Shelley Batts (who based on her pictures alone seems to be both attractive and avian-friendly) posted an analysis of a study appearing in the Journal of the Science of Food and Agriculture, which suggested that the antioxidants properties in fruits were boosted by alcohol. In other words, as this UPI article exclaims: Strawberry daiquiris, a healthier cocktail.
Great news, right? Although Batts--bravely eschewing the press release--did a thorough read of the article and found that, sure, co-mingling ethanol with strawberries and blueberries both better preserves fruit and heightens its anti-oxidant effect, but that among the other compounds tested, ethanol was neither the most effective at staving off decay nor the best at boosting anti-oxidants. Surprise, the findings were overstated by the mainstream press (as well as in the press release, courtesy of the Society of Chemical Industry.)"
Great news, right? Although Batts--bravely eschewing the press release--did a thorough read of the article and found that, sure, co-mingling ethanol with strawberries and blueberries both better preserves fruit and heightens its anti-oxidant effect, but that among the other compounds tested, ethanol was neither the most effective at staving off decay nor the best at boosting anti-oxidants. Surprise, the findings were overstated by the mainstream press (as well as in the press release, courtesy of the Society of Chemical Industry.)"
British drugmaker to buy MedImmune - baltimoresun.com
British drugmaker to buy MedImmune - baltimoresun.com: "Industry analysts had estimated MedImmune could command about $45 to $50 per share. Yesterday, they characterized the amount AstraZeneca plans to pay - reached through an intense bidding process involving multiple suitors - as a sign of desperation among pharmaceutical makers.
'There's kind of a land grab going on,' said Peter Winter, editorial director for Burrill & Co., a San Francisco merchant bank that finances biotech businesses. 'Major biotech companies are being scooped up.'"
'There's kind of a land grab going on,' said Peter Winter, editorial director for Burrill & Co., a San Francisco merchant bank that finances biotech businesses. 'Major biotech companies are being scooped up.'"
Lawmakers urges high tech, pharmaceutical industries to compromise on proposed patent reform - International Herald Tribune
Lawmakers urges high tech, pharmaceutical industries to compromise on proposed patent reform - International Herald Tribune: "At a congressional hearing Thursday, Democratic Rep. Howard Berman said the goal of legislation he introduced April 18 is to address 'the inability of the current patent laws to accommodate different business models,' rather than to favor one industry over another. Berman chairs the House Judiciary Subcommittee on Courts, the Internet and Intellectual Property, which held the hearing."
Impact China Event in Shanghai to Highlight Burgeoning R&D Outsourcing and Partnership Opportunities for Multinational Pharma, Biotech and CRO Compani
Impact China Event in Shanghai to Highlight Burgeoning R&D Outsourcing and Partnership Opportunities for Multinational Pharma, Biotech and CRO Companies: "IMPACT CHINA III: Pharmaceutical R&D Global Summit
NEW YORK--(BUSINESS WIRE)--Pharmaceutical and biotech companies from the West and Asia will convene in Shanghai this May 20-23 at “IMPACT CHINA III: Pharmaceutical R&D Global Summit” to discuss the current trends and challenges facing China’s fast-growing pharmaceutical sector. China has quickly become the international destination of choice for the multinational pharmaceutical and biotech companies who are looking to China to help strengthen and expedite their drug discovery and development efforts.
"
NEW YORK--(BUSINESS WIRE)--Pharmaceutical and biotech companies from the West and Asia will convene in Shanghai this May 20-23 at “IMPACT CHINA III: Pharmaceutical R&D Global Summit” to discuss the current trends and challenges facing China’s fast-growing pharmaceutical sector. China has quickly become the international destination of choice for the multinational pharmaceutical and biotech companies who are looking to China to help strengthen and expedite their drug discovery and development efforts.
"
California Healthcare Institute Submits Statement on Patent Reform Legislation
California Healthcare Institute Submits Statement on Patent Reform Legislation: "LA JOLLA, Calif.--(BUSINESS WIRE)--The California Healthcare Institute (CHI) today submitted a statement on H.R. 1908, The Patent Reform Act of 2007, at a hearing of the U.S. House of Representatives Committee on the Judiciary Subcommittee on Court, the Internet, and Intellectual Property. CHI is a non-profit public policy research organization for California’s biomedical industry.
"
"
Promote the Progress� ::: J. Matthew Buchanan's Patent Blog ::: Brazil is so trendy...its pharma patent-busting technique is starting to catch on
Promote the Progress� ::: J. Matthew Buchanan's Patent Blog ::: Brazil is so trendy...its pharma patent-busting technique is starting to catch on: "In the fall of 2005, Brazil successfully used the TRIPs compulsory licensing provisions as a sword to negotiate lower prices on patent-protected drugs from big pharma. Abbott flinched when faced with this novel approach, and agreed to drastic discounts to avoid an 'official' compulsory license.
Back then, I viewed the agressive actions of the Brazilian government as 'a beginning' of a new trend..."
Back then, I viewed the agressive actions of the Brazilian government as 'a beginning' of a new trend..."
Nanotechnology Offers Hope for Treating Spinal Cord Injuries, Diabetes, Heart and Parkinson's Disease, Bio/Medicine, The Project on Emerging Nanotechn
Nanotechnology Offers Hope for Treating Spinal Cord Injuries, Diabetes, Heart and Parkinson's Disease, Bio/Medicine, The Project on Emerging Nanotechnologies - NanoTechWire.com - The online resource for Nano Technology And Research: "In a dramatic demonstration of what nanotechnology might achieve in regenerative medicine, paralyzed lab mice with spinal cord injuries have regained the ability to walk using their hind limbs six weeks after a simple injection of a purpose-designed nanomaterial."
Orange Book Blog: Mylan, Apotex, and Teva File Motions Challenging FDA's Decision on Generic Norvasc
Orange Book Blog: Mylan, Apotex, and Teva File Motions Challenging FDA's Decision on Generic Norvasc: "Apparently not too many companies other than Pfizer are happy with the FDA's decision last week regarding Norvasc (amlodipine besylate) exclusivity. On Monday, Mylan, Apotex, and Teva all filed motions with the U.S. District Court for the District of Columbia for injunctive relief from FDA's decision. Today, everyone filed briefs in opposition to each others' motions."
RealClearPolitics - Articles - DNA Denied, Justice Dies
RealClearPolitics - Articles - DNA Denied, Justice Dies: "n a statistic that is both gratifying and horrifying, a Chicago Army veteran has become the 200th person to be exonerated by DNA evidence, according to the Innocence Project, a nonprofit New York-based legal clinic"
4.26.2007
Early Examples of Biotechnology
Early Examples of Biotechnology: "Modern biochemistry and microbiology techniques utilize a number of molecular techniques that have developed in the past couple of decades as a result of the discovery of PCR, DNA fingerprinting, restriction enzymes, sequencing and cloning techniques. However, before we ever knew what a gene was, humans were manipulating cells in some very industrious ways, to produce foods, chemicals or improved crops. The list below outlines some of the more historical biotechnological techniques that laid the groundwork for this area of study, before the term “biotechnology” was ever used."
IndustryWeek : Abbott Opens New Biotechnology Manufacturing Facility In Puerto Rico
IndustryWeek : Abbott Opens New Biotechnology Manufacturing Facility In Puerto Rico: "In order to support the long-term supply of its biologic agent, HUMIRA (adalimumab), as well as future biologics, Abbott opened a new biologics manufacturing facility (ABL) in Puerto on April 10."
California Stem Cell Report
California Stem Cell Report: "California Stem Cell Report
News, information and commentary on public policy and business issues involving California's new stem cell agency, the California Institute for Regenerative Medicine, created by Prop. 71. This Web page is published by David Jensen, whose background and email contact can be found on this page under oddly titled section, 'About Me.'"
News, information and commentary on public policy and business issues involving California's new stem cell agency, the California Institute for Regenerative Medicine, created by Prop. 71. This Web page is published by David Jensen, whose background and email contact can be found on this page under oddly titled section, 'About Me.'"
VentureBeat � Is Big Pharma tiptoeing into embryonic stem cells?
VentureBeat � Is Big Pharma tiptoeing into embryonic stem cells?: "By David Hamilton 04.6.07
Encapsulated islet cellsFor what appears to be the first time, a major drug company has plunked down a significant equity investment in embryonic stem cells.
Earlier today, VentureWire reported (sub required) that Novocell, an early-stage San Diego biotech that aims to treat diabetes with the embryonic cells, is hoping to raise $35 million in a third round of funding. The interesting thing, however, isn’t so much the money as the identity of the lead investor: Johnson & Johnson Development Corp., the venture arm of pharmaceutical giant J&J."
Encapsulated islet cellsFor what appears to be the first time, a major drug company has plunked down a significant equity investment in embryonic stem cells.
Earlier today, VentureWire reported (sub required) that Novocell, an early-stage San Diego biotech that aims to treat diabetes with the embryonic cells, is hoping to raise $35 million in a third round of funding. The interesting thing, however, isn’t so much the money as the identity of the lead investor: Johnson & Johnson Development Corp., the venture arm of pharmaceutical giant J&J."
Micro RNAs: The Last Frontier of Medicine?
Micro RNAs: The Last Frontier of Medicine?: "Micro RNAs (miRNA) were discovered in worms about 14 years ago, but they have been found in a wide range of organisms (including humans) in the last few years. A subset of our genes encode miRNAs which are transcribed in the usual fashion creating primary transcripts (pri-miRNA). These long single stranded pri-miRNAs fold back on themselves to create hairpin stem-loop structures. The hairpins in the pri-miRNA are cleaved into short 70 nucleotide pre-miRNAs through drosha processing. These Pre-miRNAs are then exported from the nucleus. In the cytoplasm, dicer processing takes place where the RNA-induced silencing complex (RISC) binds to the hairpin RNAs and further cuts the RNA to make the final miRNA."
Pharma Sales Reps Suing for Overtime: $1 Billion Potentially at Stake � On Pharma
Pharma Sales Reps Suing for Overtime: $1 Billion Potentially at Stake � On Pharma: "Pharmaceutical Executive’s Beth Herskovits has just reported that tens of thousands of pharma sales reps across the country are suing their current and former employees for overtime and the equivalent of “time and a half. ” $1 billion in settlements could be at stake. "
Logo Design Blog � Biotechnology Logos
Logo Design Blog � Biotechnology Logos: "Biotechnology refers to combining DNA of plants and animals for modification purposes and their use in agriculture, food science and medicine. There has been a great deal of talk - and money - poured into biotechnology with the hope that miracle drugs will appear. Some people believe that the impact of biotechnology will be on the same scale as of computers. But despite growing hype about the field, there seems to be a dearth of good design and creativity in biotechnology logos."
TCS Daily - The Angel Is in the Details
TCS Daily - The Angel Is in the Details: "Twenty years ago, then-FDA Commissioner Frank Young and I began a Wall Street Journal op-ed thus: 'Defining the terms 'biotechnology' and 'genetic engineering' isn't an easy task, since the terms don't represent natural groupings of processes or products. They connote something different to individual commentators, journalists, organizations, congressional staffers and members of the public. The terms are ambiguous, the source of much confusion and little advantage, and we would do well to return to more specific and descriptive terms.'
These observations remain valid, sad to say. Many people who use the terms 'biotechnology,' 'genetic engineering,' and 'genetically modified' don't know what they're talking about. Literally. Confusion about the terminology has led to the stigmatization of superior techniques by unscrupulous NGOs and some government officials, worthless conferences and reports, and poorly conceived experiments performed in the name of 'biotechnology risk assessment.' "
These observations remain valid, sad to say. Many people who use the terms 'biotechnology,' 'genetic engineering,' and 'genetically modified' don't know what they're talking about. Literally. Confusion about the terminology has led to the stigmatization of superior techniques by unscrupulous NGOs and some government officials, worthless conferences and reports, and poorly conceived experiments performed in the name of 'biotechnology risk assessment.' "
Health Affairs Blog
Health Affairs Blog: "Biotechnology firms constitute a subsector of the larger pharmaceutical industry (“drug companies with needles,” we call them), but to date have been spared from the blood sport of American health punditry, pharma-bashing. While drug firms routinely are castigated for their sins, real and imagined, biotech firms have been appreciated as innovative and entrepreneurial startups (rather than, say, rapacious dinosaurs with me-too molecules that overmedicate teens, overmedicalize social problems, and prostitute the Food and Drug Administration). But, given the free-floating hostility in health care, where everyone feels he is paying too much and getting too little and that someone else is to blame, biotech’s 15 minutes of fame is coming."
Biotech seeks to ease fuel's reliance on oil, corn - Turkish Daily News Apr 24, 2007
Biotech seeks to ease fuel's reliance on oil, corn - Turkish Daily News Apr 24, 2007: "The ethanol craze is putting the squeeze on corn supplies and causing food prices to rise.
Mexicans took to the streets last year to protest increased tortilla prices. The cost of chicken and beef in the United States ticked up because feed is more expensive.
That's where biotechnology comes in.
Scientists are engineering microscopic bugs to extract fuel from a variety of non-corn sources, including the human urinary tract, a Russian fungus and the plant responsible for tequila."
Mexicans took to the streets last year to protest increased tortilla prices. The cost of chicken and beef in the United States ticked up because feed is more expensive.
That's where biotechnology comes in.
Scientists are engineering microscopic bugs to extract fuel from a variety of non-corn sources, including the human urinary tract, a Russian fungus and the plant responsible for tequila."
Biotech firms should keep it simple
Biotech firms should keep it simple: "Biotechnology Association of Alabama members need to tell their companies' stories to the community, investors, partners and media to increase their visibility, association executive director Kathy Nugent said Tuesday.
And they need to ditch the scientific terms for plain language and short responses to command people's attention, said CNBC biotechnology reporter Mike Huckman. His comments were delivered during a panel discussion at BAA's annual meeting."
And they need to ditch the scientific terms for plain language and short responses to command people's attention, said CNBC biotechnology reporter Mike Huckman. His comments were delivered during a panel discussion at BAA's annual meeting."
4.25.2007
SignOnSanDiego.com > News > Business > Biotechnology -- Web site focuses on biotech jobs
SignOnSanDiego.com > News > Business > Biotechnology -- Web site focuses on biotech jobs: "A job search Web site launched yesterday by Biocom, the San Diego region's biotechnology industry trade group, aims to make getting a lead on a job or a new employee a one-stop process.
The site, www.BIOCOMCareerCenter.org, lists more than 700 jobs at California biotechnology, medical device, pharmaceutical and supply companies. The postings range from entry-level positions, such as internships, to high level jobs in management and scientific research."
The site, www.BIOCOMCareerCenter.org, lists more than 700 jobs at California biotechnology, medical device, pharmaceutical and supply companies. The postings range from entry-level positions, such as internships, to high level jobs in management and scientific research."
BioWorld Today
BioWorld Today: "The second phase of the Norwegian Functional Genomics Program (FUGE) has secured NOK420 million (US$70.3 million), which will be allocated to research programs between now and 2011, but the board responsible for the initiative is seeking an additional NOK490 million. An extra NOK45 million is being made available in October to fund industry-driven projects."
New biotech company to commercialize novel UD gene-repair technology
New biotech company to commercialize novel UD gene-repair technology: "OrphageniX Inc., a new biotechnology company founded by University of Delaware researchers, has been established in Wilmington to develop and commercialize UD-patented technologies for repairing genes that cause rare, hereditary diseases such as sickle cell anemia and spinal muscular atrophy. ...
Kmiec holds 14 UD patents for gene-editing technologies and is widely regarded as a pioneer in the field.
There are more than 5,000 rare or “orphan” diseases, so named because each affects fewer than 200,000 people nationwide. A number of these diseases are caused by a single-point mutation in a gene--which is like a spelling error, a single “letter” out of place, in its DNA code. The DNA nucleotide adenine (A), for example, might be replaced by guanine (G), cytosine (C) or thymidine (T)."
Kmiec holds 14 UD patents for gene-editing technologies and is widely regarded as a pioneer in the field.
There are more than 5,000 rare or “orphan” diseases, so named because each affects fewer than 200,000 people nationwide. A number of these diseases are caused by a single-point mutation in a gene--which is like a spelling error, a single “letter” out of place, in its DNA code. The DNA nucleotide adenine (A), for example, might be replaced by guanine (G), cytosine (C) or thymidine (T)."
Farmer Success Stories from around the World from Planting Biotech Crops
Farmer Success Stories from around the World from Planting Biotech Crops: "2007 BIO International Convention
--(BUSINESS WIRE)--2007 BIO International Convention:
WHAT: Worldwide, farmers are reaping the economic, social, and
environmental benefits of growing biotech crops. ..."
--(BUSINESS WIRE)--2007 BIO International Convention:
WHAT: Worldwide, farmers are reaping the economic, social, and
environmental benefits of growing biotech crops. ..."
California Healthcare Institute Submits Statement on Patent Reform Legislation
California Healthcare Institute Submits Statement on Patent Reform Legislation: "CHI recognizes the significant IP challenges facing software, IT and other high-tech firms – many based in California. The organization supports improving the U.S. patent system to ensure patent certainty and quality, recognizes that H.R. 1908 has certain merits, and remains committed to engaging constructively as the measure works its way through the Committee process. However, owing to the particular complexities surrounding biotechnology patents, CHI believes that some provisions of H.R. 1908 threaten life sciences investment and innovation. Specific provisions of concern to California’s life sciences innovators are: apportionment of damages for patent infringements, creating a new administrative mechanism for challenging patents throughout the life of a patent, and expanding the Patent and Trademark Office’s (PTO) rulemaking authority to enact restrictions on continuation applications and the number of claims in patent applications."
Terry Etherton Blog on Biotechnology � Ben & Jerry’s Embraces GM Ice Cream Protein?
Terry Etherton Blog on Biotechnology � Ben & Jerry’s Embraces GM Ice Cream Protein?: "Terry Etherton
According to an article published in FoodNaviator.com, Unilever, the parent company of Ben & Jerry’s, one of the most visible anti-biotechnology ice cream makers in the United States, has moved closer to gaining approval in Europe to use an ice-structuring protein (ISP) isolated from genetically modified yeast."
According to an article published in FoodNaviator.com, Unilever, the parent company of Ben & Jerry’s, one of the most visible anti-biotechnology ice cream makers in the United States, has moved closer to gaining approval in Europe to use an ice-structuring protein (ISP) isolated from genetically modified yeast."
Large Numbers of People Do Not Trust the Institutions They Identify as Most Responsible for Drug Safety
Large Numbers of People Do Not Trust the Institutions They Identify as Most Responsible for Drug Safety: "In a survey conducted by Harris Interactive(R), people were asked for their opinions regarding institutions responsible for drug safety in the United States. We found that institutions believed to have the greatest responsibility in drug safety are often those that are least trusted to do so. Among a list of four entities integral to drug safety -The Federal Drug Administration (FDA), pharmaceutical companies, doctors and other healthcare providers, and Congress - people identified the FDA and pharmaceutical companies as the entities that should bear the most responsibility for drug safety in the United States today."
Baxter Announces Carbon Neutral Headquarters
Baxter Announces Carbon Neutral Headquarters: "In a keynote address today to nearly 600 attendees at the 2007 Ceres Conference in Boston, Baxter Chairman and Chief Executive Officer Robert L. Parkinson, Jr. emphasized the important role that corporations are playing in advancing solutions to such global challenges as climate change and access to healthcare. "
Avicena's Huntington's Disease Drug Candidate Selected as One of 100 Great Investigational Drugs of 2007 by R&D Directions
Avicena's Huntington's Disease Drug Candidate Selected as One of 100 Great Investigational Drugs of 2007 by R&D Directions: "Avicena Group, Inc. (OTC Bulletin Board: AVGOE), a biotechnology company focused on commercializing its proprietary cellular energy modulation technology, announced today that the pharmaceutical magazine R&D Directions selected Avicena's lead Huntington's disease drug candidate, HD-02, as one of the '100 Great Investigational Drugs of 2007' in the March issue."
Onconome Announces Completion of Breakthrough Research Study Highlighting New Blood Test for Prostate Cancer
Onconome Announces Completion of Breakthrough Research Study Highlighting New Blood Test for Prostate Cancer: "Onconome, Inc., a privately held Seattle based biotechnology company, today announced the publication of a groundbreaking research study conducted at The Johns Hopkins School of Medicine. The study relates to a newly discovered blood protein, ProstaMark(R) EPCA-2 (Early Prostate Cancer Antigen) that could change the way men are screened for prostate cancer, a disease which kills more than 25,000 men each year."
Press Release: Merck's Singulair Wins New Asthma Indication - FierceBiotech
Press Release: Merck's Singulair Wins New Asthma Indication - FierceBiotech: "Merck's Singulair Wins New Asthma Indication
WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for SINGULAIR� (montelukast sodium) to prevent exercise-induced bronchoconstriction (EIB; also known as exercise-induced asthma) in patients aged 15 years and older. SINGULAIR is the first and only oral tablet approved for this use."
WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for SINGULAIR� (montelukast sodium) to prevent exercise-induced bronchoconstriction (EIB; also known as exercise-induced asthma) in patients aged 15 years and older. SINGULAIR is the first and only oral tablet approved for this use."
Scientists Identify Pathogens That May Be Causing Global Honeybee Deaths
Scientists Identify Pathogens That May Be Causing Global Honeybee Deaths: "Researchers have identified potential culprits behind the wide-spread catastrophic death of honeybees around North America and Europe. A team of scientists from Edgewood Chemical Biological Center and University of California San Francisco identified both a virus and a parasite that are likely behind the recent sudden die-off of honeybee colonies."
Press Release: Biotech Drug Spending Increases 21 Percent Even as Growth in Rx Expenditure Slows - FierceBiotech
Press Release: Biotech Drug Spending Increases 21 Percent Even as Growth in Rx Expenditure Slows - FierceBiotech: "Biotech Drug Spending Increases 21 Percent Even as Growth in Rx Expenditure Slows
ST. LOUIS -- Apr 25, 2007 - Express Scripts, a leading pharmacy benefit manager, today announced spending on high-cost biotech drugs increased 21 percent in 2006. This increase excludes spending for biotech drugs within the medical benefit, such as those administered in physician offices or other therapies that traditionally fall into the medical benefit. Spending increased 25 percent in 2005. Released at the company's annual Outcomes Conference, the 2006 Drug Trend Report also estimates overall biotech drug costs will reach $99 billion by 2010 accounting for 26 percent of total drug spending."
ST. LOUIS -- Apr 25, 2007 - Express Scripts, a leading pharmacy benefit manager, today announced spending on high-cost biotech drugs increased 21 percent in 2006. This increase excludes spending for biotech drugs within the medical benefit, such as those administered in physician offices or other therapies that traditionally fall into the medical benefit. Spending increased 25 percent in 2005. Released at the company's annual Outcomes Conference, the 2006 Drug Trend Report also estimates overall biotech drug costs will reach $99 billion by 2010 accounting for 26 percent of total drug spending."
Kansas City infoZine News - Corn Growers Urge Careful Marketing of New Biotechnology Trait - USA
Kansas City infoZine News - Corn Growers Urge Careful Marketing of New Biotechnology Trait - USA: " Corn Growers Urge Careful Marketing of New Biotechnology Trait
FarmersThe Missouri Corn Growers Association (MCGA) mailed letters to its membership encouraging proper stewardship of new biotechnology as it enters the marketplace."
FarmersThe Missouri Corn Growers Association (MCGA) mailed letters to its membership encouraging proper stewardship of new biotechnology as it enters the marketplace."
Pharmalot: Kennedy Circulates Biogenerics Bill
Pharmalot: Kennedy Circulates Biogenerics Bill: "April 25, 2007
Kennedy Circulates Biogenerics Bill
tedkennedy.jpg
Ted Kennedy is reported to be circulating draft legislation which would provide an approval pathway at the FDA for generic versions of biotech drugs. His proposed bill would also provide a period of market exclusivity for brand-name biotechs before generic versions of their products could come to market."
Kennedy Circulates Biogenerics Bill
tedkennedy.jpg
Ted Kennedy is reported to be circulating draft legislation which would provide an approval pathway at the FDA for generic versions of biotech drugs. His proposed bill would also provide a period of market exclusivity for brand-name biotechs before generic versions of their products could come to market."
Xenoport Sees Positive Study Data - Forbes.com
Xenoport Sees Positive Study Data - Forbes.com: "Biopharmaceutical company Xenoport Inc. said Wednesday its primary restless legs syndrome treatment candidate showed positive results in a late-stage clinical trial."
News: Celera Licenses Oncology-Related Discoveries to LabCorp. Genetic Engineering News - Biotechnology from Bench to Business
News: Celera Licenses Oncology-Related Discoveries to LabCorp. Genetic Engineering News - Biotechnology from Bench to Business: "GEN News Highlights
Celera granted Laboratory Corporation of America� Holdings (LabCorp) rights to its breast cancer metastasis and estrogen/progesterone receptor discoveries. Many of the discoveries licensed to LabCorp are involved in the p53 tumor suppressor signaling pathways and are implicated in cancer proliferation."
Celera granted Laboratory Corporation of America� Holdings (LabCorp) rights to its breast cancer metastasis and estrogen/progesterone receptor discoveries. Many of the discoveries licensed to LabCorp are involved in the p53 tumor suppressor signaling pathways and are implicated in cancer proliferation."
News: Researchers Link Gene Variations to AMD Progression. Genetic Engineering News - Biotechnology from Bench to Business
News: Researchers Link Gene Variations to AMD Progression. Genetic Engineering News - Biotechnology from Bench to Business: "GEN News Highlights
Variations of two common genes are associated with progression to more advanced forms of age-related macular degeneration (AMD), according to researchers at Tufts-New England Medical Center.
The investigators set out to assess whether certain genetic variants have prognostic importance for progression to advanced AMD and related visual loss. The study included 1,466 white participants. During the study, 281 volunteers progressed to advanced AMD in one or both eyes, which included geographic atrophy, exudative disease, or AMD causing visual loss."
Variations of two common genes are associated with progression to more advanced forms of age-related macular degeneration (AMD), according to researchers at Tufts-New England Medical Center.
The investigators set out to assess whether certain genetic variants have prognostic importance for progression to advanced AMD and related visual loss. The study included 1,466 white participants. During the study, 281 volunteers progressed to advanced AMD in one or both eyes, which included geographic atrophy, exudative disease, or AMD causing visual loss."
Biotech start-ups flush from big venture rounds - FierceBiotech
Biotech start-ups flush from big venture rounds - FierceBiotech: "U.S. biotech start-ups raked in a whopping $1.5 billion in venture funds in the first quarter, according to Thomson Financial's latest analysis on venture funding. That money was distributed in 102 deals, making biotech the hottest industry in the country for start-ups. Thomson also provided more insight into southern California's big surge in biotech venture rounds, with investors pouring a record $686 million into 44 companies in San Diego. The big numbers led Thomson Financial's Darrell Pinto to predict that 'this will be a breakout year for venture capital.'"
Patent Prospector: Junk Patents
Patent Prospector: Junk Patents: "Junk Patents
The nadir of the USPTO allowing crappy patents was over a decade ago. Now, political climate changed, the continual stench of patent reform in the air, as often as not, agency rejections border on the absurd in stringency without efficacy. Conversations with other prosecutors confirm the observation that examination without spurious noise has become the exception."
The nadir of the USPTO allowing crappy patents was over a decade ago. Now, political climate changed, the continual stench of patent reform in the air, as often as not, agency rejections border on the absurd in stringency without efficacy. Conversations with other prosecutors confirm the observation that examination without spurious noise has become the exception."
FDA to investigate Lilly's handling of Zyprexa data - FierceBiotech
FDA to investigate Lilly's handling of Zyprexa data - FierceBiotech: "The FDA has opened an inquiry to determine if Eli Lilly manipulated the data it submitted for Zyprexa, a controversial antipsychotic that has been linked to rapid weight gain and diabetes."
Biotech contenders - baltimoresun.com
Biotech contenders - baltimoresun.com: "Biotech contenders
The state has a breadth in its biotechnology companies and several possibilities to become the leader
Originally published April 25, 2007"
The state has a breadth in its biotechnology companies and several possibilities to become the leader
Originally published April 25, 2007"
Health Blog : Glaxo's Garnier on MedImmune, Pipeline and the Pound
"Glaxo’s Garnier on MedImmune, Pipeline and the Pound
Posted by Jacob Goldstein
nullGlaxoSmithKline’s first-quarter earnings are out this morning — profits are down 1.2%, and sales are down 3.8%.
The company’s chief Jean-Pierre Garnier (pictured at right) just showed up on CNBC.
A few highlights from the interview:"
Posted by Jacob Goldstein
nullGlaxoSmithKline’s first-quarter earnings are out this morning — profits are down 1.2%, and sales are down 3.8%.
The company’s chief Jean-Pierre Garnier (pictured at right) just showed up on CNBC.
A few highlights from the interview:"
Out of the Gate: BioDelivery Sciences Up - Forbes.com
"BioDelivery Sciences International Inc. shot to an all-time high Wednesday morning after the company said a trial showed its drug Bema Fentanyl was effective in reducing pain in cancer patients."
Pfizer Subsidiary Pleads Guilty to Kickback Violation and Is Sentenced to Pay Criminal Fine of $19.68 Million
"PHARMACIA AND UPJOHN COMPANY, INC., a subsidiary of Pfizer Inc., pleaded guilty today in federal court to one count of offering a kickback to a pharmacy benefit manager in the expectation of obtaining improved formulary status for PHARMACIA's drug products from the pharmacy benefit manager. The company was also sentenced at today's hearing."
The Energy Blog: Mirel Bioplastic Plant Announced by Metabolix and ADM
"In 2006, Metabolix Inc. (Nasdaq: MBLX), and Archer Daniels Midland (NYSE: ADM) formed a a 50-50 joint venture company operating under the name of Telles to commercialize Mirel(TM) Natural Plastics. The companies announced today that they will jointly produce biobased and totally biodegradable Mirel Natural Plastics."
Writers Wanted
"I’ve been hired as a freelance writer covering biotech companies for The Motley Fool, so posting frequency may drop off a little while I figure out my dual roles. I think this blog has potential and I don’t want to see it die (actually I’d like to see it grow), so if there’s anyone out there who’s interested in writing analysises on babybiotechs.com, please let me know via e-mail (it’s in the about page). The revenue sharing from the ads won’t pay the mortgage (unless you live in a trailer down by the river, then maybe it will cover it), but it will get you exposure, which might land you a job like it did me."
evolgen: Junk DNA in Scientific American
"Would I write about junk DNA? No. Never. Not me. Not even when Scientific American publishes sub par articles on junk DNA. Well, they're at it again."
Jumping 'Junk' DNA May Fuel Mammalian Evolution: Scientific American
"Tiny, jumping bits of DNA are looking less like genomic junk and more like significant players in mammalian evolution, according to a new analysis.
Researchers have uncovered more than 10,000 short stretches of what may be functional DNA in parts of the human genome with no obvious role—the so-called junk DNA that makes up 95 percent of the genome. The segments appear to be fragments of transposons, pieces of DNA capable of copying themselves and inserting into new locations, up to millions of times."
Researchers have uncovered more than 10,000 short stretches of what may be functional DNA in parts of the human genome with no obvious role—the so-called junk DNA that makes up 95 percent of the genome. The segments appear to be fragments of transposons, pieces of DNA capable of copying themselves and inserting into new locations, up to millions of times."
Dendreon: An Even Better Risk vs. Reward Scenario - Seeking Alpha
"Lets Be Reasonable submits: In my April 23rd article, 'Dendreon: Revisiting the Risk/Reward Scenario', I noted that at $15, there was $2 to $3 of downside risk for Dendreon (DNDN), with possibly $15 to $20 of upside. Given a 50/50 chance of FDA approval, I fully expected the stock price to rebound and trade in the $21 to $24 range as the May 15 date approaches."
Truth About Trade & Technology - Island Matters
"Island Matters
by: Sarah Styan
The Star-Bulletin rightly called for the governor to seek expert advice to help determine the future of crop biotechnology in Hawaii 'Genetically modified crops need scrutiny,' Our Opinion, April 6). A gathering of diverse representation from health, agriculture and other sciences would confirm that the adoption of crop biotechnology is socially responsible, beneficial to everyone and, above all, safe.
"
by: Sarah Styan
The Star-Bulletin rightly called for the governor to seek expert advice to help determine the future of crop biotechnology in Hawaii 'Genetically modified crops need scrutiny,' Our Opinion, April 6). A gathering of diverse representation from health, agriculture and other sciences would confirm that the adoption of crop biotechnology is socially responsible, beneficial to everyone and, above all, safe.
"
Glaxo's Sales Drop as Patents Expire, Guides Upbeat - Seeking Alpha
"British drugmaker GlaxoSmithKline posted earnings little changed from last year on stunted sales growth of its asthma and diabetes treatments."
Health Blog : A Strong Season for Vaccines
"April 25, 2007, 3:21 pm
A Strong Season for Vaccines
Posted by Jacob Goldstein
Novartis said today it will pay up to $500 million to license an experimental vaccine to help people quit smoking. The vaccine, from a Swiss biotech company called Cytos, is in clinical trials.
The Cytos vaccine is supposed to prompt the body to create antibodies that bind to nicotine in the blood, reducing nicotine uptake in the brain. Nabi Biopharmaceuticals is also at work on a nicotine vaccine called NicVax."
A Strong Season for Vaccines
Posted by Jacob Goldstein
Novartis said today it will pay up to $500 million to license an experimental vaccine to help people quit smoking. The vaccine, from a Swiss biotech company called Cytos, is in clinical trials.
The Cytos vaccine is supposed to prompt the body to create antibodies that bind to nicotine in the blood, reducing nicotine uptake in the brain. Nabi Biopharmaceuticals is also at work on a nicotine vaccine called NicVax."
7 Companies Searching to Treat or Cure Parkinson's - Seeking Alpha
"7 Companies Searching to Treat or Cure Parkinson's
Posted on Apr 25th, 2007 with stocks: ACAD, CEGE, NVS, SKYE, SNY, TEVA, VRX
Stockerblog submits: A good friend of mine was recently written up in the newspaper regarding a new Parkinson's disease treatment he is receiving, that involves having two holes drilled in his head. Fortunately, there are many companies researching other treatments and cures for this degenerative disorder of the central nervous system that impairs motor skills and speech. Here are some of them:"
Posted on Apr 25th, 2007 with stocks: ACAD, CEGE, NVS, SKYE, SNY, TEVA, VRX
Stockerblog submits: A good friend of mine was recently written up in the newspaper regarding a new Parkinson's disease treatment he is receiving, that involves having two holes drilled in his head. Fortunately, there are many companies researching other treatments and cures for this degenerative disorder of the central nervous system that impairs motor skills and speech. Here are some of them:"
USA for Innovation's 8 Deadly Lies About Thailand's Theft of American Innovation
"USA for Innovation (http://www.usaforinnovation.org) today announced a special report highlighting the 8 deadly lies about Thailand's theft of American innovation by the new military regime and Health Minister Mongkol na Songkhla."
North Jersey Media Group providing local news, sports & classifieds for Northern New Jersey!
"Kenneth I. Moch has played an active role in the New Jersey biotechnology industry for nearly two decades.
As the former chief executive of Alteon Inc., a biotech developing cardiovascular therapies at its Montvale headquarters, a co-founder of The Liposome Co. in Princeton, and past chairman of the Biotechnology Council of New Jersey, Moch has helped shape regional and national policy issues related to the life sciences industry."
As the former chief executive of Alteon Inc., a biotech developing cardiovascular therapies at its Montvale headquarters, a co-founder of The Liposome Co. in Princeton, and past chairman of the Biotechnology Council of New Jersey, Moch has helped shape regional and national policy issues related to the life sciences industry."
Patent Docs: Patent Profile: SinoBiomed Announces Issuance of Patent Covering Malaria Vaccine
"By Donald Zuhn --
Logo_sbm SinoBiomed announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 7,101,556, which is directed to fusion proteins comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1) and the production of anti-malarial vaccines using such proteins. In its release, SinoBiomed states that the '556 patent covers the malaria vaccine PfCP2.9, the exclusive rights to which SinoBiomed acquired through its subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co. Ltd. Shanghai Wanxing Bio-pharmaceuticals had previously acquired the rights to the '556 patent from assignee Second Military Medical University."
Logo_sbm SinoBiomed announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 7,101,556, which is directed to fusion proteins comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1) and the production of anti-malarial vaccines using such proteins. In its release, SinoBiomed states that the '556 patent covers the malaria vaccine PfCP2.9, the exclusive rights to which SinoBiomed acquired through its subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co. Ltd. Shanghai Wanxing Bio-pharmaceuticals had previously acquired the rights to the '556 patent from assignee Second Military Medical University."
Dyadic investigating potential improprieties, stock trading halted - South Florida Business Journal:
"Dyadic International said it has discovered potentially material operational and financial improprieties at its Hong Kong and mainland China operations. As a committee looks into the problems, the company's top officer is on leave and Dyadic stock trading is temporarily halted."
The Manila Times Internet Edition | OPINION >
"VIRTUAL REALITY
By Tony Lopez
Novartis sues India on patents
The giant Swiss drug multinational Novartis’ challenge to India’s patent laws could seriously reduce, if not cut the supply of affordable medicines to treat AIDS and other epidemics in poor countries."
By Tony Lopez
Novartis sues India on patents
The giant Swiss drug multinational Novartis’ challenge to India’s patent laws could seriously reduce, if not cut the supply of affordable medicines to treat AIDS and other epidemics in poor countries."
4.24.2007
Capitol Hill Watch | House Democrats Introduce Legislation That Would Allow FDA To Approve Follow-on Biologics - Kaisernetwork.org
"Reps. Jay Inslee (D-Wash.), Gene Green (D-Texas) and Tammy Baldwin (D-Wis.) on Thursday introduced legislation (HR 1956) that would allow FDA to approve follow-on biologics, CQ HealthBeat reports. Follow-on biologics are lower-cost versions of biotechnology drugs. FDA has no approval process for follow-on biologics. Under the measure introduced Thursday, drug makers would receive 14 years of data exclusivity for new follow-on biologics, with the possibility of an additional year if the HHS secretary approved the drug for a new indication that offered a "significant clinical benefit" during the 12 years following its authorization. The measure would allow the HHS secretary to issue guidance describing the data that would be required for approval of follow-on biologics in a particular class. The measure also would allow FDA to make a science-based determination about the data and information needed for approval of such drugs, including factors such as complexity and immunogenic reactions of the original product. In addition, FDA would be permitted to request comment from patient groups, brand-name drug manufacturers and generic manufacturers throughout the approval process. To ensure the safety of such drugs, FDA would be allowed to request nonclinical studies and clinical trials "at appropriate levels," according to the legislation."
Disease > Promising New Approach To Treating Genetic Disorders Reveals
"New preclinical data published online in the current edition of the journal Nature show that PTC124, an investigational new drug designed to bypass nonsense mutations, was efficacious in a preclinical model of Duchenne muscular dystrophy (DMD)."
Biogen Idec's Crowd-Pleasing Act - Preview
"MOM ALWAYS SAID, 'DON'T FOLLOW THE CROWD,' but she never worked on Wall Street, and she never invested in biotech stocks.
The biotech sector is now officially in play following AstraZeneca's $15.6 billion cash takeover of MedImmune, and speculators are placing bets about the next takeover target.
Biogen Idec, Celgene and Dendreon are attracting bullish call-trading, but the short-term momentum seems to be building behind Biogen.
Biogen stock jumped 4% on the AstraZeneca merger news. Call-trading remains active and indicates speculators are expecting Biogen stock to jump past $50 ..."
The biotech sector is now officially in play following AstraZeneca's $15.6 billion cash takeover of MedImmune, and speculators are placing bets about the next takeover target.
Biogen Idec, Celgene and Dendreon are attracting bullish call-trading, but the short-term momentum seems to be building behind Biogen.
Biogen stock jumped 4% on the AstraZeneca merger news. Call-trading remains active and indicates speculators are expecting Biogen stock to jump past $50 ..."
The Patent System
Broken?
Vonage, a leading Internet telephony company, appears before a federal appeals court today to argue that it should be allowed to continue signing up new customers while it appeals the recent verdict that its products infringe three of Verizon's patents. A Virginia jury last month ordered Vonage to pay Verizon $58 million for infringing the patents, and Vonage was barred from signing up new customers. Given Vonage's precarious financial position, a permanent ban on signing up new customers would effectively be a death sentence for the company.
The case raises some troubling questions about America's patent system, which seems to allow a deep-pocketed incumbent to drive an innovative competitor out of business. Vonage pioneered the Internet telephony market, and has enticed more than two million customers away from Verizon and other telephone industry incumbents. But while Verizon hasn't been able to stop Vonage's momentum in the marketplace, they've found more success in the courtroom.
Luminex Licenses Cystic Fibrosis Gene Patent From John Hopkins University
"Luminex Licenses Cystic Fibrosis Gene Patent From John Hopkins University "
U.S. Department of Labor's OSHA Announces Focus on Health Hazards of Microwave Popcorn Butter Flavorings Containing Diacetyl
"The U.S. Department of Labor's Occupational Safety and Health Administration (OSHA) today announced that it is initiating a National Emphasis Program (NEP) to address the hazards and control measures associated with working in the microwave popcorn industry where butter flavorings containing diacetyl are used."
IDEXX Laboratories Denied Motion That Would Have Prevented Discovery in Multi-million Dollar Antitrust Lawsuit Brought by CYNTEGRA Inc.
"IDEXX Laboratories Denied Motion That Would Have Prevented Discovery in Multi-million Dollar Antitrust Lawsuit Brought by CYNTEGRA Inc."
News: Researchers Discover Link Between White Matter and Schizophrenia. Genetic Engineering News - Biotechnology from Bench to Business
"New research explains why defects in the brain's white matter may be a key contributor to schizophrenia. The findings also demonstrate the mechanism of action of two genes already linked to the disease.
Prior studies associated the genes for neuregulin 1 (NRG1), a growth factor involved in brain development, and erbB4, a receptor on brain cells through which NRG1 exerts its action with schizophrenia. Until now, however, it hadn't been shown that alterations in these genes lead to psychiatric disorders, according to researchers at Children's Hospital Boston Neurobiology Program.
Working in a mouse model, this team demonstrated that alterations in NRG1-erbB signaling induce pathologic changes in the brain's white matter. They further show that these changes lead to alterations in biochemical signaling and to behaviors suggestive of mental illness."
Prior studies associated the genes for neuregulin 1 (NRG1), a growth factor involved in brain development, and erbB4, a receptor on brain cells through which NRG1 exerts its action with schizophrenia. Until now, however, it hadn't been shown that alterations in these genes lead to psychiatric disorders, according to researchers at Children's Hospital Boston Neurobiology Program.
Working in a mouse model, this team demonstrated that alterations in NRG1-erbB signaling induce pathologic changes in the brain's white matter. They further show that these changes lead to alterations in biochemical signaling and to behaviors suggestive of mental illness."
News: Novozymes Creates Biopharmaceutical Ingredients Business. Genetic Engineering News - Biotechnology from Bench to Business
"Novozymes set up a biopharmaceutical ingredients business to develop and manufacture animal-free recombinant ingredients to support production. The initial focus will be the launch of a range of ingredients developed specifically for industrial-scale mammalian cell culture."
News: Inactivation of Protein Reduces Damage from MS. Genetic Engineering News - Biotechnology from Bench to Business
"Scientists found that deactivating a protein, cyclophilin D, protects nerve fibers from damage in a mouse model of multiple sclerosis.
'While we can't genetically inactivate cyclophilin D in people, there are drugs out there that can block the protein,” notes Michael Forte, Ph.D., senior scientist at the Vollum Institute at Oregon Health & Science University (OHSU). “Our research predicts that drugs that block cyclophilin D should protect nerve fibers from damage in MS.'
Cyclophin D is a key regulator of molecular processes in the nerve cell's mitochondrion and can participate in nerve fiber death. Inactivating this protein strengthens the mitochondrion, helping to protect nerve fibers from injury."
'While we can't genetically inactivate cyclophilin D in people, there are drugs out there that can block the protein,” notes Michael Forte, Ph.D., senior scientist at the Vollum Institute at Oregon Health & Science University (OHSU). “Our research predicts that drugs that block cyclophilin D should protect nerve fibers from damage in MS.'
Cyclophin D is a key regulator of molecular processes in the nerve cell's mitochondrion and can participate in nerve fiber death. Inactivating this protein strengthens the mitochondrion, helping to protect nerve fibers from injury."
Las Vegas Targets Life Science and Bio Tech Companies
"LAS VEGAS, April 24 /PRNewswire/ -- Nevada Development Authority (NDA) has selected Boston for its next targeted campaign in its ongoing effort to recruit life science and bio tech companies in the region. NDA will be exhibiting at Boston's BIO 2007 International Convention from May 6-9 at the Boston Convention & Exhibition Center. It is NDA's goal to educate the approximate 20,000 convention attendees on the growing life science and bio tech infrastructure in Las Vegas while promoting the substantial benefits of a favorable tax climate, overall low costs of doing business and less bureaucratic, business-friendly state and local governments. In addition, NDA will also launch an innovative billboard campaign to educate Boston businesses and BIO 2007 attendees."
PDL BioPharma's European Patent Claims Upheld
"PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced that the Opposition Division of the European Patent Office decided today at an oral proceeding to uphold claims in the company's European Patent No. 0 451 216 ('216 patent) that are virtually identical to the claims remitted to the Opposition Division by the Board of Appeal. The patent covers the production of humanized antibody light chains that contain amino acid substitutions made under PDL's antibody humanization technology and provides specific coverage for our daclizumab antibody."
Getting High on Drug Stocks - Seeking Alpha
"Getting High on Drug Stocks
Posted on Apr 24th, 2007 with stocks: ABT, LLY, MRK, PPH, SGP
ContraHour submits: As a contrarian, I've been holding a bunch of drug stocks for the past couple of years -- and it feels like they've been hanging around my neck like Jacob Marley's ghostly chains in A Christmas Carol. But lo and behold, this month they've added to my performance for the first time in years. My first reaction was disbelief -- that outperformance may be an undigested bit of beef, a blot of mustard, a crumb of cheese, a fragment of underdone potato. My second reaction was: Bah!! Humbug!! Sell."
Posted on Apr 24th, 2007 with stocks: ABT, LLY, MRK, PPH, SGP
ContraHour submits: As a contrarian, I've been holding a bunch of drug stocks for the past couple of years -- and it feels like they've been hanging around my neck like Jacob Marley's ghostly chains in A Christmas Carol. But lo and behold, this month they've added to my performance for the first time in years. My first reaction was disbelief -- that outperformance may be an undigested bit of beef, a blot of mustard, a crumb of cheese, a fragment of underdone potato. My second reaction was: Bah!! Humbug!! Sell."
WENDMAN's VIEWS on NANOTECH: Ottawa's missing growth gene: Behind the failure of Ottawa's life sciences industry
"Ottawa's missing growth gene: Behind the failure of Ottawa's life sciences industry"
What Happens When Science Is Not Your Guide
"Following feelings - or even experience - rather than the findings of the scientific community is not the best path forward under most circumstances. A piece on calorie restriction and anorexia by a recovered anorexic at Slate is very illustrative of this point:"
Health Blog : The Trouble With Men
"The Trouble With Men
Posted by Jacob Goldstein
Men at any age are 40% more likely to die than women. They have more abdominal fat (the bad kind) and less HDL cholesterol (the good kind) than women. Men are also far less likely to visit a doctor regularly. “Most of the time, when a man shows up in my office it’s because a woman sent him,” Benjamin Brewer writes today in his online column, the Doctor’s Office. “I think that’s why married guys live longer.”"
Posted by Jacob Goldstein
Men at any age are 40% more likely to die than women. They have more abdominal fat (the bad kind) and less HDL cholesterol (the good kind) than women. Men are also far less likely to visit a doctor regularly. “Most of the time, when a man shows up in my office it’s because a woman sent him,” Benjamin Brewer writes today in his online column, the Doctor’s Office. “I think that’s why married guys live longer.”"
News: BIO to Unveil Innovative Polls Comparing Views of Top-Level Biotech Executives, Public on Key Biotech Issues. Genetic Engineering News - Biotech
"BIO to Unveil Innovative Polls Comparing Views of Top-Level Biotech Executives, Public on Key Biotech Issues
Apr 23 2007, 2:05 PM EST
Business Wire
The Biotechnology Industry Organization (BIO) will launch its 2007 BIO International Convention in Boston on May 6 with a special media-only brunch that will include the announcement of results of a one-of-a-kind public opinion research project conducted by two premier U.S. polling firms.
The research project, consistent with the theme of this year's BIO International Convention, 'New Ideas. Bold Ventures. Global Benefits,' encompasses the results of two separate polls conducted jointly by Republican and Democratic strategists. The surveys will allow pollsters for the first time to measure insider insights from top-level executives at biotechnology companies against the public's perception of the biotechnology industry and its potential to solve some of world's most pressing challenges."
Apr 23 2007, 2:05 PM EST
Business Wire
The Biotechnology Industry Organization (BIO) will launch its 2007 BIO International Convention in Boston on May 6 with a special media-only brunch that will include the announcement of results of a one-of-a-kind public opinion research project conducted by two premier U.S. polling firms.
The research project, consistent with the theme of this year's BIO International Convention, 'New Ideas. Bold Ventures. Global Benefits,' encompasses the results of two separate polls conducted jointly by Republican and Democratic strategists. The surveys will allow pollsters for the first time to measure insider insights from top-level executives at biotechnology companies against the public's perception of the biotechnology industry and its potential to solve some of world's most pressing challenges."
Malaysian trade talks stall on GM labelling
"The labelling of genetically modified (GM) goods within Malaysia has come further under the spotlight this week as the industry remains torn between its proposed bio-safety laws and free trade agreements between the US.
Under section 61 of Malaysia's proposed bio-safety bill, any GM products sold in the country would face mandatory labelling, a notion unpopular with some US biotech companies.
The issue highlights globally divided opinion regarding the use of GM products within the food chain."
Law.com - Problems With the Patent System: Nothing Cash Can't Cure
"Problems With the Patent System: Nothing Cash Can't Cure
As a new patent reform bill hits Congress, tech companies are spending big to convince legislators that change is good"
Biotech Blog � Biotech 360
"Coming soon, a new biotechnology magazine from The Scientist called Biotech 360. I’ve been asked to compile a list of the top biotechnology blogs. Want to know who made the cut? You’ll have to wait until May 10th."
Malaria-infected mice cured by 1 dose of new drug | Huliq: Breaking News
"Malaria-infected mice cured by 1 dose of new drug
Similar Stories
*
Pharmacists' Workload Contributes To Errors
*
Obesity in horses can lead to fatal problems
*
Sea snails break the law
Johns Hopkins University researchers have cured malaria-infected mice with single shots of a new series of potent, long lasting synthetic drugs modeled on an ancient Chinese herbal folk remedy.
The team also has developed several other compounds which defeated the febrile disease in rodents after three oral doses.
These peroxide compounds, containing a crucial oxygen-oxygen unit, promise not only to be more effective than today's best malaria remedies, but also potentially safer and more efficient, said research team leader Gary Posner, Scowe Professor of Chemistry in the Krieger School of Arts and Sciences at Johns Hopkins.
An article about the team's work is slated to appear on the Web on April 17 in the ASAP section of The Journal of Medicinal Chemistry. Go here: http://tinyurl.com/3cwg3a"
Genetically modified cows to produce cheap insulin - FierceBioReseacher
"Genetically modified cows to produce cheap insulin"
Genetic therapy could cure 1,800 diseases - FierceBioReseacher
"New animal research into PTC124 at the University of Massachusetts Medical School indicated that it is effective in correcting the genetic disorder that causes Duchenne muscular dystrophy in about 15 percent of cases. Researchers say that DMD is sometimes triggered when the assembly process required to make proteins necessary for good health is interfered with by a DNA 'nonsense mutation.' The therapy works by prompting cells to ignore the mutations. The therapy, which is being developed by PTC Therapeutics, is now in human trials for DMD and cystic fibrosis. Researchers, though, have been excited by the potential for PTC124 to work against up to 1800 genetic diseases also linked to the same cellular process that triggers DMD. Those diseases include Hunter syndrome and beta thalassaemia. PTC Therapeutics recently pulled a planned IPO, saying that a series of partnerships and research grants provided enough capital for now to push its development programs without a public offering."
ScienceDaily: Pancreatic Cancer Vaccine Halts Progression Of Disease In Some Patients
"A dendritic cell-based therapeutic vaccine for pancreatic cancer developed by researchers at the University of Pittsburgh School of Medicine has successfully stalled the disease from progressing in a handful of patients three years post-vaccination. The results, part of a press briefing on cancer vaccines held at the annual meeting of the American Association of Cancer Research in Los Angeles, provide promising evidence that the vaccine can trigger a patient's own immune system to rally against pancreatic cancer and offer new insights into how the vaccine could be made even more effective. The study is abstract number 4896 in the meeting proceedings."
IOL: Scientists 'manufacture' human sperm
"Hamburg - A team of scientists in Germany have 'manufactured' human sperm from bone marrow, raising the prospect of mass-producing sperm that can be used in IVF treatment or to restore fertility to men made sterile by cancer therapy."
Researchers Develop Economic System For Expanding Stem Cells To Form Cartilage Tissue
"Researchers Develop Economic System For Expanding Stem Cells To Form Cartilage Tissue"
Wired Science - Wired News
"Potential Limiter Removal Found for Adult Stem Cells
Infinitysign Adult stem cells lack two useful characteristics of their embryonic brethren: pluripotency and the capacity for long-term self-renewal. Findings from a Columbia-MIT collaboration, published today in the journal Cell, may help researchers overcome the self-renewal limitation."
Research Could Lead To Treatment For Alzheimer's Disease
"The new molecule prevents the first step in a chain of events that leads to amyloid plaque formation in the brain. The material at various stages of plaque formation is made up of fibrous clumps of toxic proteins that cause the devastating symptoms of Alzheimer's disease, said Ghosh, who has a dual appointment in the chemistry and medicinal chemistry and molecular pharmacology departments. "
Mayo Clinic Discovers DNA Repair as Key to Huntington's Disease | All American Patriots
"Poor gene repair may point to cause of incurable disease
Mayo Clinic researchers, along with collaborators from the National Institutes of Health (NIH) and University of Oslo, Norway, have discovered that a miscue of the body's genetic repair system may cause Huntington's disease, a fatal condition that affects 30,000 Americans annually by destroying their nervous system. Until now, no one knew how Huntington's begins, only that it is incurable. The findings appear in the online issue of the journal Nature."
Press Release: A Promising New Approach to Treating Genetic Disorders - FierceBioReseacher
"South Plainfield, N.J., April 23, 2007 — New preclinical data published online in the current edition of the journal Nature show that PTC124, an investigational new drug designed to bypass nonsense mutations, was efficacious in a preclinical model of Duchenne muscular dystrophy (DMD). It is estimated that approximately 13 percent of the cases of DMD are due to nonsense mutations. PTC Therapeutics, Inc., which discovered and is developing PTC124, has catalogued over 1,800 distinct genetic disorders where nonsense mutations are the cause of the disease in a significant percentage of patients. Nonsense mutations inactivate gene function and are known to cause anywhere from five to 70 percent of the individual cases of most inherited diseases, such as cystic fibrosis (10%) and Hurler’s syndrome (70%)"
Press Release: Astex Grants Cytochrome P450 License to Glaxosmithkline - FierceBiotech
"CAMBRIDGE, April 24, 2007 -- Astex Therapeutics today announced that it has granted a non-exclusive, worldwide license to its cytochrome P450 intellectual property to GlaxoSmithKline. Under the terms of the agreement, GlaxoSmithKline will pay an up-front fee to Astex in return for a license under Astex's portfolio of granted and pending cytochrome P450 patents. The specific financial terms and other details of the license were not disclosed."
Press Release: Exelixis Reinitiates Clinical Development of XL999 - FierceBiotech
"Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer"
Press Release: Pharmos Corporation Reports Mixed Mid-Stage Trial Results for Pain Reliever - FierceBiotech
"Pharmos Corporation today announced results from its Phase 2a clinical trial of the effects of intravenous (i.v.) cannabinor against post-operative pain in over 100 male patients undergoing third molar dental extraction. The single-center, randomized, double-blinded, placebo-controlled, single administration of different cannabinor doses study was conducted at the UCL (University College London) Analgesia Centre in London, UK."
Press Release: Neuromed Pharmaceuticals Licenses Phase 3 Chronic Pain Product from ALZA Corporation (JNJ) - FierceBiotech
"Neuromed Pharmaceuticals Licenses Phase 3 Chronic Pain Product from ALZA Corporation (JNJ); Neuromed to Make Upfront Payment of $30 Million"
Press Release: Amarin Corporation Says Huntington's Disease Drug Failed in Trials - FierceBiotech
"Amarin Corporation Says Huntington's Disease Drug Failed in Trials
LONDON, April 24 -- Amarin Corporation plc ('Amarin' or the 'Company') today announces top-line results from its two Phase III clinical trials of Miraxion to treat Huntington's disease (HD). The Company conducted two Phase III double-blind, placebo-controlled studies in which HD patients were randomized to receive either placebo or 2 grams (1 gram twice daily) of Miraxion daily for six months. Study data showed no statistically significant difference in either study between Miraxion and placebo with regard to the primary and secondary endpoints."
Amgen touts progress in two key programs - FierceBiotech
"With sales of its blockbuster anemia drug Aranesp slipping amid some serious questions about their safety, analysts were cheered by the news that two of the biotech giant's development programs were making positive progress. Executives announced that the osteoporosis therapy denosumab met all of its primary and secondary endpoints in a trial of 332 volunteers. And researchers reported encouraging results with AMG531, an autoimmune blood disorder drug that treats immune thrombocytopenic purpura. Overall, says Amgen, profits shot up 11 percent in the first quarter. Analysts generally applauded the news about Amgen's development programs, seeing signs that the company could weather the storm over its anemia drugs. Fariba Ghodsian, an analyst with Dafna Capital in Los Angeles, says that denosumab has the potential to go on to become a blockbuster therapy."
FDA expected to OK Pfizer HIV drug
"Analysts expect Pfizer to win approval for a first-of-a-kind drug to treat HIV despite safety concerns raised by government regulators ahead of a Tuesday meeting.
A panel of experts meets in Rockville, Md., to advise the Food and Drug Administration on whether to approve Pfizer's maraviroc to fight HIV. If approved it would be the first in a new class of treatments that block HIV from entering white blood cells through a pathway present in some patients that carry the virus."
News: Protiva Biotherapeutics Inc.: Inex Bankruptcy Petition Withdrawn. Genetic Engineering News - Biotechnology from Bench to Business
"Protiva Biotherapeutics Inc. today announced that Inex Pharmaceuticals Corporation has withdrawn, with the leave of the Supreme Court of British Columbia, its bankruptcy petition which sought to have Protiva declared bankrupt."
Press Release: FDA Approves Alpharma's KADIAN(R) New 10mg Strength - FierceBiotech
"Alpharma Inc., a global specialty pharmaceutical company, today announced that it has been notified by the United States Food and Drug Administration('FDA') that its pending application for KADIAN� 10mg strength capsule has received approval."
Press Release: China Aoxing Pharmaceutical Signs Letter of Intent to Acquire Shijiazhuang Le Ren Tang Pharmaceutical - FierceBiotech
"China Aoxing Pharmaceutical Company, Inc., one of the first non-governmental enterprises to enter the analgesic industry in China, today announced that it has signed a Letter of Intent to acquire Shijiazhuang Le Ren Tang Pharmaceutical Ltd ('LRT'). LRT is a pharmaceutical company organized under the laws of China specializing in the manufacturing and distribution of modernized Chinese traditional medicines, with a strong portfolio of pain management products."
Press Release: U.S. Venture Capital Investment Increases 8 Percent to $6.96 Billion in First Quarter of 2007 - FierceBiotech
"U.S. Venture Capital Investment Increases 8 Percent to $6.96 Billion in First Quarter of 2007
Record-Breaking Healthcare Investments and Increased Early-Stage Deal Flow, According to Dow Jones VentureOne and Ernst & Young LLP Quarterly Venture Capital Report"
Neurochem Sets Low Expectations [Fool.com] April 23, 2007
"On Thursday, specialty drug developer Neurochem (Nasdaq: NRMX) made two announcements. One was the timeline for the upcoming release of phase 3 clinical trial data for its Alzheimer's drug candidate, Alzhemed. The other was a change to how its statisticians review the data from the trial.
Neurochem completed the pivotal 1,052-person Alzhemed study in February. The upcoming clinical trial results from this study are expected to be announced sometime in the second quarter, and will determine whether the drug has any chance of achieving marketing approval without the need for more clinical trial work."
blogging various things biotech...
"Ausy Biotech ... 'Western Australia will become home to a new multi-million dollar clinical trials facility which has the potential to test new treatments for cancer, diabetes and heart disease.' more..."
blogging various things biotech...
"Drug developer Pharmos Corp. said Tuesday its postoperative pain treatment candidate showed mixed results in a midstage study. "
Court Affirms Invalidity of AstraZeneca Prilosec Process Patent - Seeking Alpha
"Aaron F. Barkoff submits: In a 2-1 decision released yesterday, the Federal Circuit affirmed a 2004 district court decision finding AstraZeneca's (AZN) U.S. Patent No. 6,013,281 invalid as inherently anticipated. The '281 patent covers a process for making Prilosec, Astra's blockbuster anti-ulcer medication."
RBC: Strong Quarter, Wellbutrin Deal Ahead for Biovail - Seeking Alpha
"Biovail Corp. (BVF), whose shares have risen more than 60% in the past six months after the company in late October 2006 hiked its dividend, said it would make a one-time payment to shareholders, dropped its U.S. sales forecast and made management changes, will likely have investors listening for news related to its Wellbutrin antidepressant when the company’s quarterly financial results come out."
Mylan Labs Gets FDA Approval for Generic Version of Ambien - Seeking Alpha
Generic and proprietary drug manufacturer Mylan Laboratories announced yesterday that the FDA has granted final approval for the release of its generic version of Sanofi-Aventis's Ambien.More at seekingalpha.
British drugmaker to buy MedImmune
London's AstraZeneca PLC said yesterday that it will pay $15.6 billion in cash to acquire FluMist developer MedImmune Inc. in a deal that highlights how far the pharmaceutical industry is willing to go to shore up its future by tapping into biotechnology.
...
The MedImmune acquisition will add 45 investigational drugs to the 113 AstraZeneca already has in its pipeline, along with three marketed products. Fifteen of the MedImmune's developing drugs are already in clinical testing.
more here.
Subscribe to:
Posts (Atom)